999 related articles for article (PubMed ID: 18981372)
1. Weight loss in Huntington disease increases with higher CAG repeat number.
Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
[TBL] [Abstract][Full Text] [Related]
2. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice.
Morton AJ; Glynn D; Leavens W; Zheng Z; Faull RL; Skepper JN; Wight JM
Neurobiol Dis; 2009 Mar; 33(3):331-41. PubMed ID: 19130884
[TBL] [Abstract][Full Text] [Related]
4. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
5. A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.
Cummings DM; Alaghband Y; Hickey MA; Joshi PR; Hong SC; Zhu C; Ando TK; André VM; Cepeda C; Watson JB; Levine MS
J Neurophysiol; 2012 Jan; 107(2):677-91. PubMed ID: 22072510
[TBL] [Abstract][Full Text] [Related]
6. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease.
Schiefer J; Landwehrmeyer GB; Lüesse HG; Sprünken A; Puls C; Milkereit A; Milkereit E; Kosinski CM
Mov Disord; 2002 Jul; 17(4):748-57. PubMed ID: 12210870
[TBL] [Abstract][Full Text] [Related]
7. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.
Lloret A; Dragileva E; Teed A; Espinola J; Fossale E; Gillis T; Lopez E; Myers RH; MacDonald ME; Wheeler VC
Hum Mol Genet; 2006 Jun; 15(12):2015-24. PubMed ID: 16687439
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone and ghrelin secretion are associated with clinical severity in Huntington's disease.
Aziz NA; Pijl H; Frölich M; Schröder-van der Elst JP; van der Bent C; Roelfsema F; Roos RA
Eur J Neurol; 2010 Feb; 17(2):280-8. PubMed ID: 19845749
[TBL] [Abstract][Full Text] [Related]
9. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
[TBL] [Abstract][Full Text] [Related]
10. The neurology and natural history of patients with indeterminate CAG repeat length mutations of the Huntington disease gene.
Panegyres PK; Goh JG
J Neurol Sci; 2011 Feb; 301(1-2):14-20. PubMed ID: 21147489
[TBL] [Abstract][Full Text] [Related]
11. Increased metabolism in the R6/2 mouse model of Huntington's disease.
van der Burg JM; Bacos K; Wood NI; Lindqvist A; Wierup N; Woodman B; Wamsteeker JI; Smith R; Deierborg T; Kuhar MJ; Bates GP; Mulder H; Erlanson-Albertsson C; Morton AJ; Brundin P; Petersén A; Björkqvist M
Neurobiol Dis; 2008 Jan; 29(1):41-51. PubMed ID: 17920283
[TBL] [Abstract][Full Text] [Related]
12. Similar Progression of Morphological and Metabolic Phenotype in R6/2 Mice with Different CAG Repeats Revealed by In Vivo Magnetic Resonance Imaging and Spectroscopy.
Sawiak SJ; Wood NI; Morton AJ
J Huntingtons Dis; 2016 Oct; 5(3):271-283. PubMed ID: 27662335
[TBL] [Abstract][Full Text] [Related]
13. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin.
Pouladi MA; Graham RK; Karasinska JM; Xie Y; Santos RD; Petersén A; Hayden MR
Brain; 2009 Apr; 132(Pt 4):919-32. PubMed ID: 19224899
[TBL] [Abstract][Full Text] [Related]
14. Clinical correlates of mitochondrial function in Huntington's disease muscle.
Turner C; Cooper JM; Schapira AH
Mov Disord; 2007 Sep; 22(12):1715-21. PubMed ID: 17557337
[TBL] [Abstract][Full Text] [Related]
15. Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease.
Dorner JL; Miller BR; Barton SJ; Brock TJ; Rebec GV
Behav Brain Res; 2007 Mar; 178(1):90-7. PubMed ID: 17239451
[TBL] [Abstract][Full Text] [Related]
16. Clinical and genetic characteristics in patients with Huntington's disease from China.
Yang J; Chen K; Wei Q; Chen Y; Cao B; Burgunder JM; Shang HF
Neurol Res; 2016 Oct; 38(10):916-20. PubMed ID: 27483361
[TBL] [Abstract][Full Text] [Related]
17. Early Neurodegeneration in R6/2 Mice Carrying the Huntington's Disease Mutation with a Super-Expanded CAG Repeat, Despite Normal Lifespan.
Kielar C; Morton AJ
J Huntingtons Dis; 2018; 7(1):61-76. PubMed ID: 29480204
[TBL] [Abstract][Full Text] [Related]
18. Parent-of-origin differences of mutant HTT CAG repeat instability in Huntington's disease.
Aziz NA; van Belzen MJ; Coops ID; Belfroid RD; Roos RA
Eur J Med Genet; 2011; 54(4):e413-8. PubMed ID: 21540131
[TBL] [Abstract][Full Text] [Related]
19. Systemic energy homeostasis in Huntington's disease patients.
Aziz NA; Pijl H; Frölich M; Snel M; Streefland TC; Roelfsema F; Roos RA
J Neurol Neurosurg Psychiatry; 2010 Nov; 81(11):1233-7. PubMed ID: 20710011
[TBL] [Abstract][Full Text] [Related]
20. Age-dependent and tissue-specific CAG repeat instability occurs in mouse knock-in for a mutant Huntington's disease gene.
Ishiguro H; Yamada K; Sawada H; Nishii K; Ichino N; Sawada M; Kurosawa Y; Matsushita N; Kobayashi K; Goto J; Hashida H; Masuda N; Kanazawa I; Nagatsu T
J Neurosci Res; 2001 Aug; 65(4):289-97. PubMed ID: 11494364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
